Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699529 | 0.95 | MEN1 (0.39) | ALDH1A1MEN1KMT2AGLP1RHPGD | |
| SCHEMBL13699523 | 0.92 | GLP1R (0.37) | MEN1KMT2AGLP1RHPGDTSHR | |
| SCHEMBL13699569 | 0.90 | MEN1 (0.36) | MEN1KMT2AGLP1RHPGDTSHR | |
| SCHEMBL13936563 | 0.90 | MEN1 (0.36) | MEN1KMT2AGLP1RHPGDTSHR | |
| SCHEMBL13936604 | 0.90 | MEN1 (0.39) | MEN1KMT2AGLP1RHPGDTSHR | |
| SCHEMBL13699632 | 0.90 | GLP1R (0.39) | MEN1KMT2AGLP1RHPGDTLR2 | |
| SCHEMBL13936543 | 0.90 | MEN1 (0.39) | ALDH1A1MEN1KMT2AGLP1RHPGD | |
| SCHEMBL16317762 | 0.88 | MEN1 (0.36) | MEN1KMT2AGLP1RHPGDTSHR | |
| SCHEMBL3484552 | 0.88 | GLP1R (0.40) | MEN1KMT2AGLP1RHPGDTSHR | |
| SCHEMBL14983962 | 0.87 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | ALDH1A1 4789/4885MEN1 1142/4885KMT2A 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.